This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Corbett CB , St Paul AK , Autieri MV
Promyelocytic leukemia protein: an atherosclerosis suppressor protein?
Clin Sci (Lond). 2021 Jul 16;135(13) :1557-1561
PMID: 34192313 URL: https://www.ncbi.nlm.nih.gov/pubmed/34192313
AbstractAs many as 70% of cells in atherosclerotic plaque are vascular smooth muscle cell (VSMC) in origin, and pathways and proteins which regulate VSMC migration, proliferation, and phenotype modulation represent novel targets for rational drug design to reduce atherosclerotic vascular disease. In this volume of Clinical Science, Karle et al. demonstrate that tumor suppressor, promyelocytic leukemia protein (PML) plays an important role in regulation of VSMC phenotype and response to inflammatory stimuli (Clin Sci (2021) 135(7), 887-905; DOI: 10.1042/CS20201399). This important work demonstrates that PML, previously unrecognized as a participant in development of atherosclerosis, may represent a novel target for anti-atherosclerotic therapeutic modalities.
Notes1470-8736 Corbett, Cali B St Paul, Amanda K Autieri, Michael V Journal Article England Clin Sci (Lond). 2021 Jul 16;135(13):1557-1561. doi: 10.1042/CS20210314.